Drug Profile
Chenodeoxycholic acid - Leadiant Biosciences
Alternative Names: Chenix; Chenodiol; Chenofalk; LB-101 - Leadiant Biosciences; LB101; XenbiloxLatest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator Dr Falk Pharma
- Developer Leadiant Biosciences; Solvay
- Class Choleretics; Cholic acids; Gallstone therapies; Gastrokinetics; Irritable bowel syndrome therapies
- Mechanism of Action Cholesterol modulators; Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cholestasis
- Registered Cerebrotendinous xanthomatosis
Most Recent Events
- 15 Feb 2024 Leadiant Biosciences plans a phase III trial for Cerebrotendinous xanthomatosis (Newly-diagnosed, In children, In adolescents, In adults, In the elderly) (PO, Capsule) in March 2024 (NCT06260748) (EudraCT2023-505759-29-00)
- 22 Mar 2022 Phase-III development in Cerebrotendinous xanthomatosis is ongoing in USA (Leadiant Biosciences pipeline, March 2022
- 01 Jun 2019 Phase-III clinical trials in Cerebrotendinous xanthomatosis in USA (PO) (Leadiant Biosciences pipeline, June 2019)